| |

High-Resolution Imaging for Mesothelioma Staging and Diagnosis

High-Resolution Imaging for Mesothelioma Staging and Diagnosis

High-resolution imaging is one of the most important tools for a clinician. A new report in the AME Surgical Journal shows the importance of better clinical imaging. It is key for accurate diagnosis and staging of malignant mesothelioma.

Malignant pleural mesothelioma is a complex disease. Mesothelioma diagnosis and accurate staging are often difficult to pin down. And the diagnosis is further complicated by different disease subtypes.

Higher resolution diagnostic imaging plays an important role in diagnosis and staging. It shows tumor thickness or volumetric data. Future updates to the cancer staging system may use clinical imaging benchmarks.

Importance and Use of Clinical Imaging

Mesothelioma causes significant morbidity and mortality. And it remains a challenging disease to diagnose and stage accurately. It is particularly hard as the different subtypes can behave differently. Yet the accurate diagnosis of subtypes and staging is very important. This is important for making treatment decisions.

Asbestos exposure causes malignant pleural mesothelioma. But it can take many decades from exposure to diagnosis. This long latency period makes exposure tracking a challenge. This can lead to a late diagnosis and a poor prognosis.

Tools like CT or MRI imaging can help with mesothelioma diagnosis, staging, and treatment planning. They give doctors a non-invasive way to look inside the body. CT is more common than MRI. But MRI imaging provides more information than a CT scan.

Most patients present with symptoms such as shortness of breath, chest pain, and a cough. So, more often than not, these patients often receive a CT scan as the first step toward diagnosis. If the CT scan suggests mesothelioma, a biopsy is often the next step.

A biopsy is important for diagnosis and for creating a treatment plan. PET scans have also been useful in determining the spread of the disease. And MRI scans have been a tool in determining if a tumor is able to be surgically removed.

Understanding Staging and Diagnosis

Staging is the process of determining how advanced a patient’s cancer is. It involves looking at various different factors and assigning a rating between 0 and 4. A higher stage indicates more extensive cancer.

International staging guidelines try to optimize care for mesothelioma patients.

The current classification system is in its eighth edition. The International Mesothelioma Interest Group (IMIG) publishes the staging guidelines for malignant pleural mesothelioma.

The latest edition has a few changes from previous guidelines. Previous editions focused on the surgical management of the disease. The latest guidelines highlight the importance of higher-resolution imaging.

The Future of Staging

Malignant pleural mesothelioma remains a challenge to diagnose and treat. The increased combination of advanced imaging choices will likely aid in diagnosis and staging. Future staging guidelines for malignant pleural mesothelioma will likely focus on imaging.

Dr. Sean Jordan of the University of Tennessee says, “Advancements in diagnosis will predictably go hand-in-hand with more precise staging systems that will overall improve prognostication and survival.”

Diagnostic techniques may affect future treatment options. A high-resolution diagnostic imaging is important in diagnosis and staging. And future updates to the staging system may include some of this image data.

Source:

Jordan, Sean, Lindsay Nitsche, and Sai Yendamuri. “Narrative review of staging and diagnosis of malignant pleural mesothelioma.” AME Surgical Journal (2022). https://cdn.amegroups.cn/journals/pbpc/files/journals/11/articles/57545/public/57545-PB5-5306-R3.pdf

 

Similar Posts

  • |

    Mesothelioma Blood Test May Be Possible

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

  • | |

    Inflammation Both “Friend and Foe” in Mesothelioma

    An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…

  • |

    New Prognostic Factor in Peritoneal Mesothelioma

    Malignant peritoneal mesothelioma is a rare form of mesothelioma that attacks the membrane that lines the abdomen and surrounds internal organs. The outlook for this rare malignancy, which affects fewer than 500 Americans annually, has been improved by the treatment combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The combination has produced 5-year overall survival rates ranging from 29% to 63%. But not all peritoneal mesothelioma patients are good candidates for CRS/HIPEC. The challenge, for clinicians, is identifying which patients are likely to benefit from the procedure (or even be cured) and which are not. In an effort to help answer that question, French researchers recently tested the prognostic value of the glucose transporter protein GLUT1 as well as…

  • | |

    FDG PET-CT Results Could Lead to Improved Mesothelioma Treatment

    In a recent study, researchers say a better understanding of certain diagnostic criteria could result in more targeted treatments for malignant mesothelioma. In a recent published report, doctors from the medical school at Dicle University in Diyarbakir, Turkey measured the relationship between PET-CT scan results and survival in 177 patients with malignant pleural mesothelioma. The patients were diagnosed between April 2007 and April 2011. They had a mean age of 55.4 and most (56%) were male. Patients in the study all had FDG PET-CT scans before beginning their mesothelioma treatment. FDG PET-CT scanning is a powerful imaging tool for mesothelioma and other cancers that combines a radioactive tracer with a combination of positron emission tomography and computed tomography scanning.  Because…

  • | |

    Mesothelioma Surgeons Report New Biopsy Technique

    A team of surgeons in Maryland have demonstrated how using a standard biopsy tool in a new way could improve the biopsy process for certain mesothelioma patients. An aggressive cancer of the pleural lining around the lungs, malignant pleural mesothelioma usually requires a tissue biopsy to make a definitive diagnosis. Often this is done using a rigid tool called a thoracoscope inserted into the chest wall while the patient is under general anesthesia. However, mesothelioma doctors at Walter Reed National Military Medical Center detail the case of a 79-year-old suspected mesothelioma patient whose biopsy was done in a minimally-invasive way, under conscious sedation, thanks to the novel use of a standard tool. Although the patient had several of the common signs…